Stocks: Vigilant Capital Management LLC Has $194,000 Position in Allergan plc (AGN)

Stocks: Vigilant Capital Management LLC Has $194,000 Position in Allergan plc (AGN)

Vigilant Capital Management LLC continued to hold its stake in shares of Allergan plc (NYSE:AGN) during the first quarter, Holdings Channel reports. The firm owned 814 shares of the company’s stock at the end of the first quarter. Vigilant Capital Management LLC’s holdings in Allergan plc were worth $194,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Crestwood Advisors Group LLC bought a new stake in shares of Allergan plc during the first quarter valued at about $103,000. Feltz Wealth PLAN Inc. bought a new stake in shares of Allergan plc during the first quarter valued at about $107,000. Sunbelt Securities Inc. bought a new stake in shares of Allergan plc during the fourth quarter valued at about $107,000. Citizens Financial Group Inc RI boosted its stake in shares of Allergan plc by 133.9% in the third quarter. Citizens Financial Group Inc RI now owns 601 shares of the company’s stock valued at $138,000 after buying an additional 344 shares during the period. Finally, Security National Trust Co. boosted its stake in shares of Allergan plc by 46.2% in the first quarter. Security National Trust Co. now owns 633 shares of the company’s stock valued at $151,000 after buying an additional 200 shares during the period. 86.40% of the stock is currently owned by institutional investors and hedge funds.

Shares of Allergan plc (NYSE:AGN) opened at 230.971 on Friday. Allergan plc has a 12 month low of $184.50 and a 12 month high of $261.27. The stock has a market cap of $77.40 billion, a price-to-earnings ratio of 7.197 and a beta of 1.07. The firm has a 50-day moving average price of $239.15 and a 200-day moving average price of $222.31.

Allergan plc (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. The company had revenue of $3.57 billion for the quarter, compared to analyst estimates of $3.53 billion. Allergan plc had a net margin of 100.04% and a return on equity of 7.21%. Allergan plc’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the business earned $3.04 EPS. Equities analysts expect that Allergan plc will post $16.09 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Thursday, May 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Tuesday, May 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.21%.

Several brokerages have issued reports on AGN. Royal Bank of Canada increased their target price on Allergan plc from $279.00 to $284.00 and gave the company an “outperform” rating in a research report on Wednesday. Citigroup Inc reaffirmed a “focus list” rating and set a $261.27 price target (up previously from $184.50) on shares of Allergan plc in a research report on Friday, April 21st. Credit Suisse Group AG reaffirmed a “buy” rating and set a $274.00 price target on shares of Allergan plc in a research report on Tuesday, February 14th. Goldman Sachs Group Inc cut Allergan plc from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research report on Wednesday. Finally, Leerink Swann set a $271.00 price target on Allergan plc and gave the stock a “buy” rating in a research report on Thursday, February 2nd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $267.21.

In related news, Director Paul Bisaro sold 70,000 shares of Allergan plc stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $246.68, for a total transaction of $17,267,600.00. Following the transaction, the director now owns 274,226 shares in the company, valued at approximately $67,646,069.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Allergan plc Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Related posts

Leave a Comment